From Glaucoma To Bioprocessing
Tuesday’s screens surfaced three different ways healthcare innovation can translate into growth: expanding access to glaucoma treatments, wider adoption of a liver-directed cancer therapy, and recovering demand for bioprocessing equipment.
The first is Tuesday’s #10 Portfolio Armor Top Name. Top Names are the securities our system estimates will have the highest returns over the next six months. The other two are favored by accounts on our Multibaggers list, a group we track because its members have identified multiple recent stocks that gained 100% or more.
All three stocks are above their 50-day exponential moving averages and pass our proprietary Trend & Consolidation screen on Chartmill. Each order uses an asymmetric bullish options structure, with its entry limit set near values produced by three option-pricing models.
New to our alerts? Start Here explains how we select trades, set entry prices and exits, and track every completed result.
Today’s Top Names Trade
Theme: Expanding access to glaucoma treatment.
RSI: 46 · Technical: 8/10 · Setup: 6/10 · Fundamental: 4/10
